Kallyope's Discovery Research Into The Gut-Brain Axis Advances
Executive Summary
Emerging Company Profile: Kallyope is translating early research of the gut-brain axis into small molecules that could have potential in a wide range of therapy areas. The company closed an $87m Series B funding round last year.
You may also be interested in...
Finance Watch: iTeos, Pandion And Aspen Show COVID-19 Hasn’t Slowed VC Deals Yet
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.
Finance Watch: Polaris Piles On As Multiple Life Science VCs Raise New Funds
Private Company Edition: Polaris is raising up to $400m for its next tech and health care fund, following in the footsteps of several life science investors this year. Also, Nevakar raises $50m in a product financing agreement and RAPT closes a $37m series C extension.
Finance Watch: Alternative Funding Sources Crucial Even Amidst A Biopharma VC Boom
Private Company Edition: Investments by CIRM, the GHIT fund and the European Investment Bank back early-stage science and treatments for neglected diseases. Also, Versant Ventures raises $700m in two funds. In VC deals, Akero raised $70m, Impel NeuroPharma brought in $67.5m.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: